In a Phase 2 trial, DR10624 — a first-of-its-kind agent that targets FGF21, glucagon, and GLP-1 pathways — significantly lowered triglycerides and improved liver health markers. Such multi-receptor drugs could reshape treatment of metabolic causes of liver disease.

At the EASL Congress 2025, hepatology experts highlighted new therapies aimed at pruritus (intense itching), a debilitating symptom of primary biliary cholangitis (PBC). These novel agents are progressing through clinical development and may soon expand the options for symptom relief.